KBC Group’s Olema Pharmaceuticals OLMA Stock Holding History

KBC Group’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,164	Closed	-$17K	–	1869
2026 Q1	$17K	Buy	+1,164	New	+$25.9K	﹤0.01%	1846
2025 Q1	–	Sell	-4,075	Closed	-$24K	–	1891
2024 Q4	$24K	Buy	+4,075	New	+$40.7K	﹤0.01%	1829

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

KBC Group's OLMA Position: Q2 2026 in Review

KBC Group sold out of Olema Pharmaceuticals (OLMA) in Q2 2026, closing a stake of 1,164 shares — an estimated $17K sold.

KBC Group first reported a position in OLMA in Q4 2024 and held it in 2 quarters. The position peaked at $24K in Q4 2024. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

KBC Group reported no remaining Olema Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
KBC Group sold 1,164 Olema Pharmaceuticals shares in Q2 2026, an estimated $17K.
KBC Group first reported a position in Olema Pharmaceuticals in Q4 2024 and held it in 2 quarters.
KBC Group's Olema Pharmaceuticals position peaked at $24K in Q4 2024.
186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.